Effect of oral iron chelation therapy with deferiprone (L1) on the psychosocial status of thalassaemia patients

被引:0
|
作者
Zahed, L [1 ]
Mourad, FH [1 ]
Alameddine, R [1 ]
Aoun, S [1 ]
Koussa, S [1 ]
Taher, A [1 ]
机构
[1] Amer Univ Beirut, Med Ctr, Dept Pathol & Lab Med, Beirut, Lebanon
关键词
oral chelation; psychosocial status; thalassaemia;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
beta-Thalassemia requires life-long treatment, including regular blood transfusion and daily iron chelation by desferrioxamine, which places considerable burden on the social and psychological life of patients. It is expected that oral chelation therapy, which is easier to administer, would improve their psychosocial status. In this sutdy, interviews were conducted with a series of 44 patients recently placed on oral chelation therapy to evaluate their reactions to the new treatment. Eighty-six per cent of patients complied better with the oral chelation therapy. Fifty per cent of patients mentioned that relief from the desferrioxamine pump was the major improvement, while 47% felt psychologically better. Fifty per cent of patients noted improvements in their relationships, while 63% noted increased social activities. Evaluation of a larger sample of patients over a longer period of time is needed in order to confirm the favourable results obtained in this study.
引用
收藏
页码:333 / 339
页数:7
相关论文
共 50 条
  • [1] Oral deferiprone for iron chelation in people with thalassaemia
    Fisher, Sheila A.
    Brunskill, Susan J.
    Doree, Carolyn
    Chowdhury, Onima
    Gooding, Sarah
    Roberts, David J.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (08):
  • [2] Oral deferiprone for iron chelation in people with thalassaemia
    Roberts, D. J.
    Brunskill, S. J.
    Doree, C.
    Williams, S.
    Howard, J.
    Hyde, C. J.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2007, (03):
  • [3] Analysis of fall in serum ferritin after chelation of iron with Deferiprone (L1) in β-thalassaemia and haemoglobin E β-thalassaemia
    Department of Haematology, Kothart Medical Centre, 8/3 Alipore Road, Calcutta 700 027, India
    不详
    Curr. Sci., 8 (839-840):
  • [4] Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1)
    Kontoghiorghes, GJ
    Pattichi, K
    Hadjigavriel, M
    Kolnagou, A
    TRANSFUSION SCIENCE, 2000, 23 (03): : 211 - 223
  • [5] Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1)
    Rombos, Y
    Tzanetea, R
    Konstantopoulos, K
    Simitzis, S
    Zervas, C
    Kyriaki, P
    Kavouklis, M
    Aessopos, A
    Sakellaropoulos, N
    Karagiorga, M
    Kalotychou, V
    Loukopoulos, D
    HAEMATOLOGICA, 2000, 85 (02) : 115 - 117
  • [6] NEW CONCEPTS OF IRON AND ALUMINUM CHELATION-THERAPY WITH ORAL L1 (DEFERIPRONE) AND OTHER CHELATORS - A REVIEW
    KONTOGHIORGHES, GJ
    ANALYST, 1995, 120 (03) : 845 - 851
  • [7] ORAL IRON CHELATION WITH L1
    AGARWAL, MB
    VISWANATHAN, C
    RAMANATHAN, J
    MASSIL, DE
    SHAH, S
    GUPTE, SS
    VASANDANI, D
    PUNIYANI, RR
    LANCET, 1990, 335 (8689): : 601 - 601
  • [8] Efficacy of combined chelation therapy with subcutaneous desferrioxamine and oral deferiprone in patients with thalassaemia major
    Francis, S
    McGirr, M
    Browne, E
    Berdoukas, V
    Lindeman, R
    BLOOD, 2003, 102 (11) : 517A - 517A
  • [9] Clinical trial of deferiprone iron chelation therapy in β-thalassaemia/haemoglobin E patients in Thailand
    Pootrakul, P
    Sirankapracha, P
    Sankote, J
    Kachintorn, U
    Maungsub, W
    Sriphen, K
    Thakernpol, K
    Atisuk, K
    Fucharoen, S
    Chantraluksri, U
    Shalev, O
    Hoffbrand, AV
    BRITISH JOURNAL OF HAEMATOLOGY, 2003, 122 (02) : 305 - 310
  • [10] FUTURE OF ORAL IRON CHELATOR DEFERIPRONE (L1)
    MEHTA, J
    SINGHAL, S
    MEHTA, BC
    LANCET, 1993, 341 (8858): : 1480 - 1480